Table 1.
Positive responses based on cell proliferation after Schu‐S4 exposure measured by incorporation of [3H]‐thymidine
|
Time Post‐Vaccination |
Group a | |||
|---|---|---|---|---|
| DVC‐LVS | USAMRIID‐LVS | |||
| n b /N (%) | 95% CI | n/N (%) | 95% CI | |
| Day 8 | 21/100 (21.0) | 13.5, 30.3 | 16/107 (15.0) | 8.8, 23.1 |
| Day 14 | 32/99 (32.3) | 23.3, 42.5 | 26/104 (25.0) | 17.0, 34.4 |
| Day 28 | 59/99 (59.6) | 49.3, 69.3 | 64/103 (62.1) | 52.0, 71.5 |
| Day 56 | 70/99 (70.7) | 60.7, 79.4 | 71/102 (69.6) | 59.7, 78.3 |
| Day 180 | 58/89 (65.2) | 54.3, 75.0 | 67/94 (71.3) | 61.0, 80.1 |
| Any (8–180) | 92/102 (90.2) | 82.7, 95.2 | 95/108 (88.0) | 80.3, 93.4 |
a
Per‐protocol population.
b
Positive criteria: (1) Visit (SCHU‐S4 [cpm]/Media [cpm]) ≥ 3, (2) Visit (SCHU‐S4 [cpm] − Media [cpm]) > 500 cpm and (3) Visit (SCHU‐S4 [cpm]/Media [cpm]) ≥ 2 × baseline (day 0) (SCHU‐S4 [cpm]/Media [cpm]).